Additionally, a recent study has shown that the BM microenvironment is responsible for early resistance of FLT3-ITD+ AML cells to FLT3 inhibition, followed by clonal expansion of pre-existing NRAS mutant subclones that drive relapse (Joshi et al., 2021). The gene discussed is FLT3; the disease is acute myeloid leukemia.